David McIntyre

David John McIntyre is currently Director at Vytronus, Inc. since 2014; Director at Tendyne Holdings, Inc.; Independent Non-Executive Director at Starpharma Holdings Ltd. since 2020; Treasurer, Chief Financial Officer, Director & EVP at Braeburn, Inc. since 2016; Director at Petalion Therapeutics Ltd.; Trustee at Fisher House Foundation, Inc. since 2010; Member of The Law Society of New South Wales; and Chief Financial Officer at Inhibikase Therapeutics, Inc. starting 2025.
Former positions include Director at Avedro, Inc., Gala Therapeutics, Inc., Tusker Medical, Inc., and ROX Medical, Inc.; Independent Non-Executive Director at Redflex Holdings Pty Ltd.; Non-Executive Director at ROX Medical, Inc.; CFO, Secretary & Chief Business Officer at Heartware Pty Ltd.; Senior Attorney at Baker & McKenzie LLP (Illinois) and KPMG Legal in 2003; Chief Financial Officer at AVITA Medical Pty Ltd. from 2019 to 2020; Chief Operating & Financial Officer & Executive VP at HeartWare International LLC in 2011; Chief Financial Officer at Tessa Therapeutics Ltd from 2020 to 2021; Chief Financial Officer at Anthos Therapeutics, Inc. from 2021 to 2024; Chief Financial Officer at AVITA Medical, Inc.; and Partner at Apple Tree Venture Management LLC from 2012 to 2020.
Education includes undergraduate studies at The University of Sydney, graduate studies at the University of Technology Sydney, and an MBA from The Fuqua School of Business.